Literature DB >> 8713682

Structure-activity relationships for 4-anilinoquinazolines as potent inhibitors at the ATP binding site of the epidermal growth factor receptor in vitro.

W A Denny1, G W Rewcastle, A J Bridges, D W Fry, A J Kraker.   

Abstract

1. Structure-activity relationships are described for the inhibition of the tyrosine kinase activity (phosphorylation of a fragment of phospholipase Cg1) of the epidermal growth factor receptor (EGFR) by 4-anilinoquinazolines. These compounds are competitive inhibitors at the ATP binding site. 2. The preferred side chain is anilino-, substituted at the 3-position with small lipophilic groups. The quinazoline moiety is absolutely required for activity, but substituents on the quinazoline greatly modulate potency, with electron-donating groups favoured. The most potent analogue, the 6,7-dimethoxy derivative (compound 20), has an IC50 of 29 pmol/L and a very high selectivity for the EGFR over other tyrosine kinase enzymes. 3. The present study shows that it is possible to identify small molecules that are very potent, yet highly selective, inhibitors of a single component of the growth signal transduction pathway in cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8713682     DOI: 10.1111/j.1440-1681.1996.tb02752.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  3 in total

1.  Antibacterial effect of some 2,6-disubstituted 4-anilinoquinazolines.

Authors:  R Gottasová; J Kubíková; L Cipák
Journal:  Folia Microbiol (Praha)       Date:  1998       Impact factor: 2.099

Review 2.  HER-2-directed, small-molecule antagonists.

Authors:  Michelle Arkin; Mark M Moasser
Journal:  Curr Opin Investig Drugs       Date:  2008-12

3.  Synthesis and In Vitro Cytotoxicity of the 4-(Halogenoanilino)-6-bromoquinazolines and Their 6-(4-Fluorophenyl) Substituted Derivatives as Potential Inhibitors of Epidermal Growth Factor Receptor Tyrosine Kinase.

Authors:  Malose Jack Mphahlele; Hugues K Paumo; Yee Siew Choong
Journal:  Pharmaceuticals (Basel)       Date:  2017-11-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.